Drugs / 18F-FMAU
18F-FMAU
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04752267 | Feb 2021 → Sep 2023 | breast carcinoma, colon carcinoma, cutaneous melanoma, glioma +3 | University of Southern California | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02809690 | Sep 2016 → Jul 2021 | prostate neoplasm | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-FMAU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04752267 ↗ |
| Known as | 5-METHYL-2'-FLUOROARAURACIL F-18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL475717 ↗ |
| Known as | D-fmau f-18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL475717 ↗ |
| Known as | Fmau f-18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL475717 ↗ |
| Known as | J2.616.188F | ChEMBL registry synonym — accepted as the source's own label CHEMBL475717 ↗ |
| Modality | Diagnostic / imaging agent | “a radioactive tracer (a drug that is visible during an imaging test)” NCT04752267 ↗ |
| Route | Intravenous | “Patients receive radiotracer F 18 d-FMAU intravenously (IV) over 1 minute” NCT02809690 ↗ |